Explicit interaction information from WikiPathways in RDF facilitates drug discovery in the Open PHACTS Discovery Platform [version 2; referees: 2 approved]
Ryan A. Miller,
Peter Woollard,
Egon L. Willighagen,
Daniela Digles,
Martina Kutmon,
Antonis Loizou,
Andra Waagmeester,
Stefan Senger,
Chris T. Evelo
Affiliations
Ryan A. Miller
Department of Bioinformatics (BiGCaT), Maastricht University, Maastricht, The Netherlands
Peter Woollard
GlaxoSmithKline (GSK), Stevenage, UK
Egon L. Willighagen
Department of Bioinformatics (BiGCaT), Maastricht University, Maastricht, The Netherlands
Daniela Digles
Pharmacoinformatics Research Group, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria
Martina Kutmon
Department of Bioinformatics (BiGCaT), Maastricht University, Maastricht, The Netherlands
Antonis Loizou
Blue Sky IT, Amsterdam, The Netherlands
Andra Waagmeester
Department of Bioinformatics (BiGCaT), Maastricht University, Maastricht, The Netherlands
Stefan Senger
GlaxoSmithKline (GSK), Stevenage, UK
Chris T. Evelo
Department of Bioinformatics (BiGCaT), Maastricht University, Maastricht, The Netherlands
Open PHACTS is a pre-competitive project to answer scientific questions developed recently by the pharmaceutical industry. Having high quality biological interaction information in the Open PHACTS Discovery Platform is needed to answer multiple pathway related questions. To address this, updated WikiPathways data has been added to the platform. This data includes information about biological interactions, such as stimulation and inhibition. The platform's Application Programming Interface (API) was extended with appropriate calls to reference these interactions. These new methods of the Open PHACTS API are available now.
